Skip to main content

Table 2 Signal detection for anticancer agent-associated mild hypersensitivity reactions

From: Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

 

N

PRR (χ2)

ROR (95% two-sided CI)

IC (95% two-sided CI)

EBGM (95% one-sided CI)

paclitaxel

228

2.768 * (254.855)

2.788 * (2.438, 3.117)

1.450 * (1.262, 1.638)

2.707 * (2.425)

docetaxel

79

1.087 (0.463)

1.087 (0.871, 1.302)

0.109 (-0.209, 0.427)

1.073 (0.890)

doxorubicin

101

1.074 (0.445)

1.074 (0.884, 1.265)

0.095 (-0.187, 0.376)

1.064 (0.902)

5-fluorouracil

108

1.365 (10.154)

1.366 * (1.130, 1.601)

0.436 * (0.164, 0.708)

1.344 (1.145)

cyclophosphamide

110

0.791 (5.894)

0.790 (0.655, 0.925)

-0.342 (-0.612, -0.073)

0.788 (0.673)

  1. The total number of co-occurrences with mild hypersensitivity reactions was 43,288.
  2. N: the number of co-occurrences of each anticancer agent out of 43,288 pairs, PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean.
  3. *: signal detected, see "Methods" for the detection criteria.